CD8A and neoplasm: After tumours became palpable, we adoptively transferred 10 x 106 MNP-labelled CD45.1+ OVA peptide-specific OT-I CD8 T cells, monitored their in vivo trafficking by whole body MPI, and performed endpoint analysis of the cells by flow cytometry 7 days after OT-I cell transfer (Figure 7A).